Back
 JBM  Vol.7 No.6 , June 2019
Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients
Abstract: With the recent development and clinical application, immune checkpoint inhibitors (ICIs) intervention is being increasingly common for multiple malignancies. With these, prospect on focus creates an increasing necessity for an early recognition with proper documentation of upcoming treatment-related toxicities. These treatment-related toxicities are generally termed as immune-related adverse effects (irAEs) [1]. It is a known fact that the upregulation of T-cell initiates autoimmunity resulting in these irAEs. The review focuses on increasing events of neuropathy associated with immunecheckpoint inhibitors, which is one of the rare neurological irAEs, therefore, the least reviewed. The severity and distribution of neurologic toxicities are important deciding factors for its management (CNS vs. PNS), although there is no strong evidence for patients treated with ICIs are specifically affected by the use of immune-modulating interventions. Furthermore, the review discusses on pathophysiology, incidence, clinical presentation, diagnosis, and management of neuropathies as a result of ICIs. Early administration of high-dose corticosteroids is the main management of neuropathies especially for grade 3 or 4 irAEs initial cessation of ICI therapy with continued steroids which are necessary. However, the optimal duration of ICI therapy to minimize the risk of toxicity should be kept under consideration.
Cite this paper: Khanal, S. and Zhang, H. (2019) Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients. Journal of Biosciences and Medicines, 7, 1-12. doi: 10.4236/jbm.2019.76001.
References

[1]   Ribas, A. (2015) Releasing the Brakes on Cancer Immunotherapy. The New England Journal of Medicine, 373, 1490-1492.
https://doi.org/10.1056/NEJMp1510079

[2]   Tosti, G., Cocorocchio, E. and Pennacchioli, E. (2013) Anti-Cytotoxic T Lymphocyte Antigen-4 Antibodies in Melanoma. Clinical, Cosmetic and Investigational Dermatology, 6, 245.
https://doi.org/10.2147/CCID.S24246

[3]   Psimaras, D. (2018) Neuromuscular Complications of Immune Checkpoint Inhibitors. La Presse Médicale, 47, 253-259.
https://doi.org/10.1016/j.lpm.2018.10.009

[4]   Touat, M., Talmasov, D., Ricard, D. and Psimaras, D. (2017) Neurological Toxicities Associated with Immune-Checkpoint Inhibitors. Current Opinion in Neurology, 30, 659-668.
https://doi.org/10.1097/WCO.0000000000000503

[5]   Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10.
https://doi.org/10.1016/j.immuni.2013.07.012

[6]   Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer, 12, 252.
https://doi.org/10.1038/nrc3239

[7]   Umezu, D., Okada, N., Sakoda, Y., Adachi, K., Ojima, T., Yamaue, H., et al. (2019) Inhibitory Functions of PD-L1 and PD-L2 in the Regulation of Anti-Tumor Immunity in Murine Tumor Microenvironment. Cancer Immunology, Immunotherapy, 68, 201-211.
https://doi.org/10.1007/s00262-018-2263-4

[8]   Ascierto, P.A., Del Vecchio, M., Robert, C., Mackiewicz, A., Chiarion-Sileni, V., Arance, A., et al. (2017) Ipilimumab 10 mg/kg versus Ipilimumab 3 mg/kg in Patients with Unresectable or Metastatic Melanoma: A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 18, 611-622.
https://doi.org/10.1016/S1470-2045(17)30231-0

[9]   Pitt, J.M., Vétizou, M., Daillère, R., Roberti, M.P., Yamazaki, T., Routy, B., et al. (2016) Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 44, 1255-1269.
https://doi.org/10.1016/j.immuni.2016.06.001

[10]   Gangadhar, T.C. and Vonderheide, R.H. (2014) Mitigating the Toxic Effects of Anticancer Immunotherapy. Nature Reviews Clinical Oncology, 11, 91.
https://doi.org/10.1038/nrclinonc.2013.245

[11]   Michot, J., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., et al. (2016) Immune-Related Adverse Events with Immune Checkpoint Blockade: A Comprehensive Review. European Journal of Cancer, 54, 139-148.
https://doi.org/10.1016/j.ejca.2015.11.016

[12]   Buchbinder, E.I. and Desai, A. (2016) CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. American Journal of Clinical Oncology, 39, 98.
https://doi.org/10.1097/COC.0000000000000239

[13]   Varricchi, G., Galdiero, M.R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., et al. (2017) Cardiotoxicity of Immune Checkpoint Inhibitors. ESMO Open, 2, Article ID: 000247.
https://doi.org/10.1136/esmoopen-2017-000247

[14]   de Cos Escuín, J.S. (2017) Nueva inmunoterapia y cáncer de pulmón. Archivos de Bronconeumología, 53, 682-687.
https://doi.org/10.1016/j.arbres.2017.06.016

[15]   Hottinger, A.F. (2016) Neurologic Complications of Immune Checkpoint Inhibitors. Current Opinion in Neurology, 29, 806-812.
https://doi.org/10.1097/WCO.0000000000000391

[16]   Bompaire, F., Mateus, C., Taillia, H., De Greslan, T., Lahutte, M., Sallansonnet-Froment, M., et al. (2012) Severe Meningo-Radiculo-Nevritis Associated with Ipilimumab. Investigational New Drugs, 30, 2407-2410.
https://doi.org/10.1007/s10637-011-9787-1

[17]   Manousakis, G., Koch, J., Sommerville, R.B., El-Dokla, A., Harms, M.B., Al-Lozi, M.T., et al. (2013) Multifocal Radiculoneuropathy during Ipilimumab Treatment of Melanoma. Muscle & Nerve, 48, 440-444.
https://doi.org/10.1002/mus.23830

[18]   Larkin, J., Chmielowski, B., Lao, C.D., Hodi, F.S., Sharfman, W., Weber, J., et al. (2017) Neurologic Serious Adverse Events Associated with Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. The Oncologist, 22, 709-718.
https://doi.org/10.1634/theoncologist.2016-0487

[19]   Dalakas, M.C. (2018) Neurological Complications of Immune Checkpoint Inhibitors: What Happens When You “Take the Brakes off” the Immune System. Therapeutic Advances in Neurological Disorders, 11, Article ID: 1756286418799864.
https://doi.org/10.1177/1756286418799864

[20]   Liao, B., Shroff, S., Kamiya-Matsuoka, C. and Tummala, S. (2014) Atypical Neurological Complications of Ipilimumab Therapy in Patients with Metastatic Melanoma. Neuro-Oncology, 16, 589-593.
https://doi.org/10.1093/neuonc/nou001

[21]   Gaudy-Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M.-A. and Grob, J.-J. (2013) A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy: A Differential Diagnosis for Ipilimumab-Induced Colitis. Journal of Immunotherapy, 36, 77-78.
https://doi.org/10.1097/CJI.0b013e31827807dd

[22]   Gu, Y., Menzies, A.M., Long, G.V., Fernando, S. and Herkes, G. (2017) Immune Mediated Neuropathy Following Checkpoint Immunotherapy. Journal of Clinical Neuroscience, 45, 14-17.
https://doi.org/10.1016/j.jocn.2017.07.014

[23]   Boisseau, W., Touat, M., Berzero, G., Savatovsky, J., Marabelle, A., Touitou, V., et al. (2017) Safety of Treatment with Nivolumab after Ipilimumab-Related Meningoradiculitis and Bilateral Optic Neuropathy. European Journal of Cancer, 83, 28-31.
https://doi.org/10.1016/j.ejca.2017.05.036

[24]   Wilgenhof, S. and Neyns, B. (2011) Anti-CTLA-4 Antibody-Induced Guillain-Barré Syndrome in a Melanoma Patient. Annals of Oncology, 22, 991-993.
https://doi.org/10.1093/annonc/mdr028

[25]   Nishijima, T.F., Shachar, S.S., Nyrop, K.A. and Muss, H.B. (2017) Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis. The Oncologist, 22, 470-479.
https://doi.org/10.1634/theoncologist.2016-0419

[26]   Antonia, S.J., López-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P., et al. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate 032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895.
https://doi.org/10.1016/S1470-2045(16)30098-5

[27]   Weber, J.S., Gibney, G., Sullivan, R.J., Sosman, J.A., Slingluff Jr., C.L., Lawrence, D.P., et al. (2016) Sequential Administration of Nivolumab and Ipilimumab with a Planned Switch in Patients with Advanced Melanoma (CheckMate 064): An Open-Label, Randomised, Phase 2 Trial. The Lancet Oncology, 17, 943-955.
https://doi.org/10.1016/S1470-2045(16)30126-7

[28]   Weber, J.S., Hodi, F.S., Wolchok, J.D., Topalian, S.L., Schadendorf, D., Larkin, J., et al. (2017) Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma. Journal of Clinical Oncology, 35, 785-792.
https://doi.org/10.1200/JCO.2015.66.1389

[29]   Horvat, T.Z., Adel, N.G., Dang, T.-O., Momtaz, P., Postow, M.A., Callahan, M.K., et al. (2015) Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients with Melanoma Treated with Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 33, 3193.
https://doi.org/10.1200/JCO.2015.60.8448

[30]   Zimmer, L., Goldinger, S.M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., et al. (2016) Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 210-225.
https://doi.org/10.1016/j.ejca.2016.02.024

[31]   de Maleissye, M.-F., Nicolas, G. and Saiag, P. (2016) Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. New England Journal of Medicine, 375, 296-297.
https://doi.org/10.1056/NEJMc1515584

[32]   Tchapyjnikov, D. and Borst, A.J. (2017) Immune-Related Neurological Symptoms in an Adolescent Patient Receiving the Checkpoint Inhibitor Nivolumab. Journal of Immunotherapy, 40, 286-288.
https://doi.org/10.1097/CJI.0000000000000177

[33]   Vallet, H., Gaillet, A., Weiss, N., Vanhaecke, C., Saheb, S., Touitou, V., et al. (2016) Pembrolizumab-Induced Necrotic Myositis in a Patient with Metastatic Melanoma. Annals of Oncology, 27, 1352-1353.
https://doi.org/10.1093/annonc/mdw126

[34]   Pushkarevskaya, A., Neuberger, U., Dimitrakopoulou-Strauss, A., Enk, A. and Hassel, J.C. (2017) Severe Ocular Myositis after Ipilimumab Treatment for Melanoma: A Report of 2 Cases. Journal of Immunotherapy, 40, 282-285.
https://doi.org/10.1097/CJI.0000000000000178

[35]   Williams, T.J., Benavides, D.R., Patrice, K.-A., Dalmau, J.O., De ávila, A.L.R., Le, D.T., et al. (2016) Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurology, 73, 928-933.
https://doi.org/10.1001/jamaneurol.2016.1399

[36]   Sivan, A., Corrales, L., Hubert, N., Williams, J.B., Aquino-Michaels, K., Earley, Z.M., et al. (2015) Commensal Bifidobacterium Promotes Antitumor Immunity and Facilitates anti-PD-L1 Efficacy. Science, 350, 1084-1089.
https://doi.org/10.1126/science.aac4255

[37]   Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. (2015) Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. New England Journal of Medicine, 372, 2006-2017.
https://doi.org/10.1056/NEJMoa1414428

[38]   Gutzmer, R., Koop, A., Meier, F., Hassel, J.C., Terheyden, P., Zimmer, L., et al. (2017) Programmed Cell Death Protein-1 (PD-1) Inhibitor Therapy in Patients with Advanced Melanoma and Preexisting Autoimmunity or Ipilimumab-Triggered Autoimmunity. European Journal of Cancer, 75, 24-32.
https://doi.org/10.1016/j.ejca.2016.12.038

[39]   Maul, L.V., Weichenthal, M., Kahler, K.C. and Hauschild, A. (2016) Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient with Known Severe Autoimmune Disease. Journal of Immunotherapy, 39, 188-190.
https://doi.org/10.1097/CJI.0000000000000118

[40]   Johnson, D.B., Sullivan, R.J., Ott, P.A., Carlino, M.S., Khushalani, N.I., Ye, F., et al. (2016) Ipilimumab Therapy in Patients with Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2, 234-240.
https://doi.org/10.1001/jamaoncol.2015.4368

 
 
Top